FATE THERAPEUTICS INC Fair Value Adjustment of Warrants
FATE THERAPEUTICS INC (FATE) reported Fair Value Adjustment of Warrants of -$35.00 thousand for the 83-month period ending 2014-03-31, per its 10-Q filed 2014-05-13.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2016-03-03
- FATE THERAPEUTICS INC fair value adjustment of warrants for the quarter ending 2013-12-31 was $29.00K.
- FATE THERAPEUTICS INC fair value adjustment of warrants for the quarter ending 2013-09-30 was -$31.00K.
- FATE THERAPEUTICS INC fair value adjustment of warrants for the quarter ending 2013-06-30 was $22.00K.
- FATE THERAPEUTICS INC fair value adjustment of warrants for the quarter ending 2013-03-31 was -$12.00K.
- FATE THERAPEUTICS INC fair value adjustment of warrants for fiscal 2013 was $8.00K.
- FATE THERAPEUTICS INC fair value adjustment of warrants for fiscal 2012 was -$37.00K.
- FATE THERAPEUTICS INC fair value adjustment of warrants for fiscal 2011 was -$5.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 77 month | Fair Value Adjustment of Warrants 80 month | Fair Value Adjustment of Warrants 83 month |
|---|---|---|---|---|---|---|---|
| 2014-03-31 | -$35.00K 10-Q · filed 2014-05-13 | ||||||
| 2013-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | -$2.00K derived: sum of 2 quarters · filed 2016-03-03 | $20.00K derived: sum of 3 quarters · filed 2016-03-03 | $8.00K 10-K · filed 2016-03-03 | -$35.00K 10-K · filed 2014-03-17 | ||
| 2013-09-30 | -$31.00K 10-Q · filed 2014-11-12 | -$9.00K derived: sum of 2 quarters · filed 2014-11-12 | -$21.00K 10-Q · filed 2014-11-12 | -$23.00K derived: sum of 4 quarters · filed 2015-03-12 | -$64.00K 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $22.00K 10-Q · filed 2014-08-12 | $10.00K 10-Q · filed 2014-08-12 | $8.00K derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$12.00K 10-Q · filed 2014-05-13 | -$14.00K derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$37.00K 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | -$35.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | -$5.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |